Casini Alessandro, Fontana Pierre, Glauser Frédéric, Robert-Ebadi Helia, Righini Marc, Blondon Marc
Service d'angiologie et d'hémostase, HUG et Faculté de médecine, 1205 Genève.
Rev Med Suisse. 2020 May 6;16(692):951-954.
Since the SARS-CoV-2 pandemic outbreak, growing evidence suggests that patients suffering from COVID-19 are at increased risk of thrombotic events. The sepsis-related activation of the coagulation combined with a high prevalence of common thrombotic risk factors could contribute to this prothrombotic state. Coagulation biomarkers could help in the identification of patients at risk of complications and mortality. The incidence of venous thromboembolic events appears to be increased, especially in severe COVID-19 patients. Based on that knowledge, several societies have provided recommendation on the prevention of venous thromboembolism. In this narrative review, we summarize available epidemiologic data on venous thromboembolism and recommendations on thromboprophylaxis in COVID-19.
自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行爆发以来，越来越多的证据表明，新冠肺炎患者发生血栓形成事件的风险增加。与脓毒症相关的凝血激活，再加上常见血栓形成风险因素的高流行率，可能导致这种血栓前状态。凝血生物标志物有助于识别有并发症和死亡风险的患者。静脉血栓栓塞事件的发生率似乎有所增加，尤其是在重症新冠肺炎患者中。基于这一认识，多个学会已就静脉血栓栓塞的预防提供了建议。在本叙述性综述中，我们总结了关于静脉血栓栓塞的现有流行病学数据以及新冠肺炎血栓预防的建议。
